Biocon to make 3 generic drugs in China

Biocon to make 3 generic drugs in China

Hot News
1 min read
Biocon. (Photo: Twitter/@Bioconlimited)
Bengaluru, Sep 14 (IANS) Biotechnology major Biocon would make three generic drugs for hard-selling in China through partnership, the company said on Saturday.
"We have signed an agreement with the subsidiary of China Medical System Holdings Ltd (CMS) to develop, manufacture and supply three generic drugs in the Chinese market," the city-based firm said in a statement.
The 10-year agreement envisages Biocon to supply the products to CMS for selling in mainland China.
"The foray into China is a part of our long-term generic formulations strategy to expand our business in the Chinese pharmaceuticals market," said the statement.
As the world's second largest pharma market, the addressable market size for the three drugs is about $800 million (Rs 5,680 crore), according to IQVIA, a US multinational firm that serves health IT and clinical research.
"The collaboration with CMS will allow us to take our US approved generic formulations to patients in China with an early entry," said Biocon Chief Executive Arun Chandavarkar in the statement.
The company, however, did not specify the diseases which the three generic drugs will aim to treat.

(This story was auto-published from a syndicated feed. No part of the story has been edited by The Quint.)

(The Quint is available on Telegram. For handpicked stories every day, subscribe to us on Telegram)

We'll get through this! Meanwhile, here's all you need to know about the Coronavirus outbreak to keep yourself safe, informed, and updated.

Liked this story? We'll send you more. Subscribe to The Quint's newsletter and get selected stories delivered to your inbox every day. Click to get started.

The Quint is available on Telegram & WhatsApp too, click to join.

Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!